GYRE trades 188.1% below Wall Street's consensus target of $17.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes GYRE achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 1 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of October 22, 2026, Gyre Therapeutics, Inc. (GYRE) has a Wall Street consensus price target of $17.00, based on estimates from 1 covering analysts. With the stock currently trading at $5.90, this represents a potential upside of +188.1%. The company has a market capitalization of $539M.
Analyst price targets range from a low of $16.00 to a high of $18.00, representing a 12% spread in expectations. The median target of $17.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 1 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, GYRE trades at a trailing P/E of 262.2x. Analysts expect EPS to grow -132.3% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 HALOHalozyme Therapeutics, Inc. | $14.8B | $124.83 | $110.00 | -11.9% | Buy | 14.5x | 27 |
 ARDXArdelyx, Inc. | $773M | $3.13 | $13.00 | +315.3% | Buy | — | 16 |
 PRAXPraxis Precision Medicines, Inc. | $7.2B | $256.47 | $611.69 | +138.1% | Buy | — | 18 |
 ACADACADIA Pharmaceuticals Inc. | $3.5B | $20.19 | $29.95 | +48.3% | Buy | 32.4x | 37 |
 INVAInnoviva, Inc. | $1.5B | $20.91 | $38.00 | +81.7% | Buy | 8.6x | 10 |
 IDYAIDEAYA Biosciences, Inc. | $3.1B | $35.47 | $57.00 | +60.7% | Buy | — | 26 |
 RCUSArcus Biosciences, Inc. | $2.4B | $19.10 | $40.00 | +109.4% | Buy | — | 18 |
 TGTXTG Therapeutics, Inc. | $8.1B | $53.20 | $80.50 | +51.3% | Buy | 53.2x | 13 |
 FOLDAmicus Therapeutics, Inc. | $4.5B | $14.49 | $14.86 | +2.6% | Buy | 40.6x | 24 |
 IMVTImmunovant, Inc. | $5.9B | $28.38 | $40.00 | +40.9% | Buy | — | 23 |
Quick answers to the most common questions about buying GYRE stock.
The consensus Wall Street price target for GYRE is $17, representing 188.1% upside from the current price of $5.9. With 1 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
GYRE has a consensus rating of "Buy" based on 1 Wall Street analysts. The rating breakdown is predominantly bullish, with 1 Buy/Strong Buy ratings. The consensus 12-month price target of $17 implies 188.1% upside from current levels.
GYRE's current price is $5.9 with a consensus target of $17 (188.1% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $18 for GYRE, while the most conservative target is $16. The consensus of $17 represents the median expectation. These targets typically reflect 12-month expectations.
GYRE is lightly followed, with 1 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 1 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month GYRE stock forecast based on 1 Wall Street analysts shows a consensus price target of $17, with estimates ranging from $16 (bear case) to $18 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on GYRE, with a "Buy" consensus rating and $17 price target (188.1% upside). 1 of 1 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
GYRE analyst price targets range from $16 to $18, a 12% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $17 consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.